

Editorial Staff, World Journal of Hepatology,

We are excited to submit this manuscript, *Psychosocial Assessment and Monitoring in the New Era of Non-Interferon-Alpha HCV Treatments*, for consideration as a Minireview by the World Journal of Hepatology. In this manuscript, we review the way that the need for psychosocial assessment and monitoring in HCV treatment will be changing with the advent of all-pill, high-efficacy direct-acting antiviral regimens that include no interferon-alpha or ribavirin. We make this assessment based on reviewing the data from efficacy studies to determine the psychosocial burden involved in these treatments.

We believe this review will help the readership World Journal of Hepatology consider these issues, and be able to develop clinical views based on such empirical data.

We have no competing interests, whether commercial, personal, political, intellectual, or religious, in relation to the submitted work.

This review draws upon previously published data, and no original data, so no institutional review board approval was needed, and no consenting of any participants was required; it is also noted that the authors have no conflicts of interest.

Sincerely,



Paul J. Rowan, Ph.D., M.P.H.
Assistant Professor
Division of Management, Policy, and Community Health
The University of Texas-Houston School of Public Health

1200 Herman Pressler Street
Houston, Texas 77030
(713) 500-9183 phone
(713) 500-9171 fax
Paul.J.Rowan@uth.tmc.edu